Trial Profile

A Phase I Clinical Trial to Evaluate VY-HTT01 for the Treatment of Huntington's Disease

Status: Suspended

Phase of Trial: Phase I

Latest Information Update: 27 Apr 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Apr 2021 According to a Voyager Therapeutics media release, the FDA decision was made following a comprehensive review of the Chemistry, Manufacturing and Controls information previously submitted by the company and the trial is expected to start this year.
26 Apr 2021 According to a Voyager Therapeutics media release, the U.S. Food and Drug Administration (FDA) has removed its clinical hold on the Investigational New Drug (IND) application for VY-HTT01 and confirmed that the company may proceed with this trial.
09 Nov 2020 According to a Voyager Therapeutics media release, the Company expects to begin the trial following clearance of the IND by the FDA.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com